CL2014001255A1 -
Use of a combination of famotidine-dexrabeprazole or famotidine-rabeprazole for the treatment of gastroesophageal reflux disease (erge), nocturnal acid leakage (ean), peptic ulcer and / or eradication of h. pylori; composition containing a proton pump inhibitor and an h2 antagonist; and its manufacturing process.
- Google Patents
Use of a combination of famotidine-dexrabeprazole or famotidine-rabeprazole for the treatment of gastroesophageal reflux disease (erge), nocturnal acid leakage (ean), peptic ulcer and / or eradication of h. pylori; composition containing a proton pump inhibitor and an h2 antagonist; and its manufacturing process.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alparis Sa De CvfiledCriticalAlparis Sa De Cv
Publication of CL2014001255A1publicationCriticalpatent/CL2014001255A1/en
CL2014001255A2013-06-182014-05-13
Use of a combination of famotidine-dexrabeprazole or famotidine-rabeprazole for the treatment of gastroesophageal reflux disease (erge), nocturnal acid leakage (ean), peptic ulcer and / or eradication of h. pylori; composition containing a proton pump inhibitor and an h2 antagonist; and its manufacturing process.
CL2014001255A1
(en)
Use of a combination of famotidine-dexrabeprazole or famotidine-rabeprazole for the treatment of gastroesophageal reflux disease (erge), nocturnal acid leakage (ean), peptic ulcer and / or eradication of h. pylori; composition containing a proton pump inhibitor and an h2 antagonist; and its manufacturing process.
Compounds derived from 1-aryl-2-imino-1,2-dihydropyridine-3-carboxamide, alpha 1d adrenergic receptor antagonist, pharmaceutical composition comprising them; and its use for the treatment or prophylaxis of diseases of the lower urinary tract.
Aqueous acid formulation comprising a first fluorocarbon linked peptide; method to obtain said formulation; use of said formulation to treat or prevent pathogenic infection, an autoimmune disease or cancer.
Process for preparing a pharmaceutical composition comprising i) providing a first combination comprising a peptide proteasome inhibitor compound, one or more cyclodextrins and water, and ii) contacting the first combination with an acid to form a second combination; pharmaceutical composition
Semisolid topical composition comprising pirfenidone, diallyl disulfide modified oxide (odd-m), a gelling agent and other excipients or additives; process to manufacture it; treatment method; and its use to eliminate, reduce or prevent acne.
Pharmaceutical composition comprising an isolated antibody that specifically binds to the stem cell factor; antibody production method; and its use to treat or prevent a disease of tissue or fibrotic remodeling in a subject.
Process for producing a fluid transfer surface comprising providing a titanium surface, subjecting it to hardening and etching; method to repair a transfer surface; and use of a fluid transfer surface.